645 results match your criteria: "John Theurer Cancer Center[Affiliation]"

Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world.

View Article and Find Full Text PDF

Background: Esophageal cancer (EC) is the sixth leading cause of cancer-related mortality worldwide, continuing to be a significant public health concern. The purpose of this study is to assess the impact of staging and histopathology of EC on associated mortality. The study also aims to further investigate clinical characteristics, prognostic factors, and survival outcomes in patients diagnosed with EC between 2010 and 2017.

View Article and Find Full Text PDF

Purpose: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL).

Patients And Methods: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles.

View Article and Find Full Text PDF

Purpose: We conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphoma (cHL; ClinicalTrials.gov identifier: NCT03033914).

Methods: Patients age ≥60 years with newly diagnosed, any stage, cHL were treated with six cycles of AVD at standard doses plus nivolumab 240 mg intravenously once every 2 weeks (on days 1 and 15) of each cycle.

View Article and Find Full Text PDF

Venetoclax, the first-in-class BCL-2 inhibitor, has shown efficacy in multiple myeloma (MM), particularly in patients with the t(11;14) translocation. This single-center retrospective analysis included MM patients treated with venetoclax from November 2017 to March 2023. Data encompassed demographics, disease characteristics, treatment regimens, and outcomes using median progression-free-survival (mPFS).

View Article and Find Full Text PDF

Interferon-alpha has activity against multiple myeloma. Modakafusp alfa is an immunocytokine comprising two attenuated interferon-alpha2b molecules and an anti-CD38 IgG4 antibody, targeting delivery of interferon-alpha to CD38+ immune and myeloma cells. This phase I/II trial (NCT03215030) enrolled patients with relapsed/refractory multiple myeloma with ≥3 prior lines of treatment and refractory to or intolerant of ≥1 proteasome inhibitor and ≥1 immunomodulatory drug.

View Article and Find Full Text PDF

Chronic Myelomonocytic Leukemia (CMML) is a rare and aggressive form of leukemia with characteristics of both myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDSs). This study aims to explore the clinical features, survival outcomes, and prognostic factors in CMML patients over the past 20 years using a large sample. The study data from 4124 patients diagnosed with CMML between 2000 and 2017 were sourced from the SEER database.

View Article and Find Full Text PDF

Mosunetuzumab and other CD20/CD3 bispecific antibodies (BsAbs) have efficacy in B-cell lymphomas relapsing after or refractory to CD19-directed chimeric antigen receptor-modified T cells (CAR-T). The optimal timing of BsAbs and biomarkers of BsAb response after CAR-T are unknown. We addressed these questions using clinical data and blood samples from patients previously treated with CAR-T treated on a phase I/II study of mosunetuzumab (clinicaltrials.

View Article and Find Full Text PDF

Purpose: Despite growing research on financial toxicity among cancer survivors, large gaps remain in understanding how to intervene to minimize financial toxicity. Uptake and efficacy of interventions mitigating cancer financial toxicity, though promising, remain limited and inconsistent. To date, survivor preferences for financial toxicity interventions are underexplored.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers are testing valemetostat, an EZH2 and EZH1 inhibitor, for safety and effectiveness in patients with relapsed or refractory non-Hodgkin lymphoma, due to limited treatment options and poor outcomes.
  • The study involved 90 participants from 19 hospitals across Japan and the USA, who received varying doses of valemetostat in a phase 1 clinical trial to find the right dosage and assess its anti-tumor effects.
  • Initial findings will help determine the most effective dosages and provide insights into the drug's safety profile, with a majority of patients having peripheral T-cell lymphoma.
View Article and Find Full Text PDF

Allogeneic stem cell transplantation (allo-SCT) has seen limited use in treating multiple myeloma (MM), despite its potential to offer long-term survival or even cure through the graft-versus-myeloma effect. Its limited application is largely due to concerns over serious complications like infections and graft-versus-host disease (GVHD). The possibility of GVHD exacerbation when CAR-T cells are administered to patients previously treated with allo-SCT remains a topic of concern.

View Article and Find Full Text PDF

Introduction: Treatment decision-making for multiple myeloma (MM) is complex. Individuals involved in decision-making may value treatment attributes differently based on their role as a patient, care partner, or physician. This study describes those attributes, and what is most important by role.

View Article and Find Full Text PDF

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.

Leukemia

December 2024

Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, University Medical Center, Rotterdam, The Netherlands.

Article Synopsis
  • Epcoritamab, a bispecific antibody targeting CD3 and CD20, showed promising long-term results as a monotherapy for relapsed or refractory large B-cell lymphoma (LBCL) in the EPCORE NHL-1 study, with a 63.1% overall response rate and a 40.1% complete response rate after a median follow-up of 25.1 months.
  • The estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively, with 64.2% of complete responders maintaining their response at that time.
  • Most treatment-emergent adverse events were manageable, with cytokine release syndrome
View Article and Find Full Text PDF

Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice.

Haematologica

September 2024

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA; Hackensack Meridian School of Medicine, Nutley, NJ, USA; Department of Oncology, Georgetown University, Washington, DC, USA; Department of Pediatrics, Hackensack University Medical Center, Hackensack, NJ.

Article Synopsis
View Article and Find Full Text PDF

The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma.

Clin Lymphoma Myeloma Leuk

August 2024

Hackensack Meridian Health, John Theurer Cancer Center, Hackensack, NJ.

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by production of abnormal levels of a monoclonal immunoglobulin or plasma cell deposition that leads to end organ destruction. The disease remains incurable despite advances in combination treatments with classes of medications that include proteosome inhibitors, immunomodulating agents, monoclonal antibodies, small molecule inhibitors, alkylating agents, T-cell-based immunotherapies, and others. Checkpoint inhibitors (CKP-I), though showing robust efficacy in solid tumor and lymphoma, have had limited success as single agents in the treatment of MM.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on patients with relapsed or refractory multiple myeloma (RRMM) who previously received lenalidomide, examining the effectiveness of a treatment combination involving pomalidomide, daratumumab, and dexamethasone (DPd).
  • During the trial, a total of 112 patients were treated, with a median overall survival (OS) of 56.7 months after 41.9 months of follow-up, showing promising results.
  • The treatment was generally safe, with adverse events leading to discontinuation in a small percentage of patients, suggesting that this combination therapy could be a viable option for RRMM patients needing further treatment post-lenalidomide.
View Article and Find Full Text PDF

Background And Purpose: The aim of this study was to determine the prevalence of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) meeting high-risk criteria for early relapse after CD19 CAR T-cell therapy (CART) who have disease encompassable in a standard radiation therapy (RT) plan (defined as <5 malignant lesions) and may benefit from bridging RT prior to CD19 CART.

Materials And Methods: This is a single-center, retrospective study of patients with R/R NHL who received CD19 CART from 2018 to 2022. Eligible patients had pre-apheresis radiologic studies available.

View Article and Find Full Text PDF

Background: Non-secretory multiple myeloma (NSMM) accounts for approx. 2-3% of multiple myeloma (MM) cases. Due to the rare occurrence and ineligibility of patients with NSMM to participate in clinical trials, we have limited data on treatment efficacy and the clinical course in these patients.

View Article and Find Full Text PDF

Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was well tolerated without dose-limiting toxicity.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the effectiveness of epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) by comparing it to other therapies used after at least two prior treatments, using advanced statistical methods to ensure fair comparisons.
  • - Epcoritamab showed significantly better response and overall survival rates than traditional chemoimmunotherapy (CIT) and other novel therapies, such as polatuzumab-based and tafasitamab-based regimens.
  • - However, there were no significant differences in response or survival rates when comparing epcoritamab to CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma.
View Article and Find Full Text PDF

Allogeneic stem cell transplantation (Allo-SCT) implies that a donor and a recipient are not genetically identical. Allo-SCT is used to cure a variety of conditions, including hematologic malignancies using the graft versus tumor effect, nonmalignant hematologic, immune deficiencies, and, more recently, genetic disorders and inborn errors of metabolism. Given the immunosuppressive and myeloablative nature of some of the conditioning chemotherapy regimens used during the Allo-SCT, patients are often at high risk of infection, including viral infections affecting the gastrointestinal tract, following the transplant.

View Article and Find Full Text PDF